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Objectives. This study investigated the neuronal reuptake of
norepinephrine (uptake-1) and the beta-adrenoceptor density in
patients with idiopathic right ventricular outflow tract tachycar-
dia (RVO-VT).
Background. Clinical findings, such as the inducibility of
ventricular tachycardia by stress or catecholamine infusion, and
the therapeutic efficacy of antiarrhythmic drugs with antiadren-
ergic properties suggest abnormalities of cardiac sympathetic
innervation in patients with idiopathic RVO-VT.
Methods. Eight patients with idiopathic RVO-VT and a total of
29 age-matched control subjects were investigated by positron
emission tomography using [11C]hydroxyephedrine (HED) (vol-
ume of distribution of [11C]HED) to assess presynaptic norepi-
nephrine reuptake; [11C]CGP 12177 (maximal binding capacity of
[11C]CGP 12177) to measure postsynaptic beta-adrenoceptor
density; and oxygen-15–labeled water for quantification of myo-
cardial blood flow (MBF).
Results. Both myocardial catecholamine reuptake and beta-
adrenoceptor density were significantly reduced in patients with
idiopathic RVO-VT. The volume of distribution of [11C]HED in
patients with RVO-VT was (mean 6 SD) 41.0 6 13.5 versus 71.0 6
18.8 ml/g in control subjects (p < 0.002). The maximal binding
capacity of the beta-adrenoceptor antagonist [11C]CGP 12177 was
6.8 6 1.2 pmol/g in patients with RVO-VT versus 10.2 6
2.9 pmol/g in control subjects (p < 0.004). There were no
significant differences in MBF at rest (0.98 6 0.14 vs. 0.97 6
0.24 ml/min per g, p 5 NS) between patients with RVO-VT and
control subjects.
Conclusions. The findings of the present study suggest that
myocardial beta-adrenoceptor downregulation in patients with
RVO-VT occurs subsequently to increased local synaptic catechol-
amine levels caused by impaired catecholamine reuptake.
(J Am Coll Cardiol 1998;32:181–6)
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In 1922, Gallaverdin (1) reported repetitive monomorphic
ventricular tachycardia originating in the right ventricle in
patients with an otherwise apparently normal heart. Until now,
despite the increasing availability of a variety of diagnostic
methods, including electrophysiologic study and endomyocar-
dial biopsy, there exists a group of patients with right ventric-
ular tachycardia (idiopathic right ventricular outflow tract
tachycardia [RVO-VT]), of which the underlying pathophysi-
ologic mechanism is not completely known (2–4). Typically
affecting young patients, RVO-VT causes palpitation, dizzi-
ness, syncope and, sometimes, sudden cardiac death (5).
RVO-VT is characterized by commonly provocable tachyar-
rhythmias under physical exercise conditions, first described by
Wilson et al. (6) in 1932, or by catecholamine infusion during
electrophysiologic studies (7). Typically, the tachycardias can
be suppressed by an antiarrhythmic drug regimen with antiad-
renergic properties, which is suggestive of an involvement of
the cardiac sympathetic nervous system in the pathophysiology
of RVO-VT (8). Regional alteration of the presynaptic re-
uptake of norepinephrine (uptake-1) associated with ventric-
ular arrhythmia has been suggested on the basis of reduced
uptake of the norepinephrine analogue [123I]meta-iodo-
benzylguanidine ([123I]MIBG) in other diseases without struc-
tural abnormalities of the heart (9–11), and in arrhythmogenic
right ventricular cardiomyopathy (12), global alteration of
presynaptic function measured by [3H]norepinephrine spill-
over was found in patients with sustained ventricular tachyar-
rhythmias and coronary artery disease (13).
On the basis of these studies, we hypothesized that presyn-
aptic reuptake of norepinephrine may be reduced in RVO-VT,
which in turn would lead to an increased concentration of
norepinephrine in the synaptic cleft and downregulation of
the postsynaptic beta-adrenoceptors. To test this hypothesis,
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we assessed presynaptic uptake-1 and postsynaptic beta-
adrenoceptor density in the myocardium of patients with
idiopathic RVO-VT by means of positron emission tomography
(PET) with the norepinephrine analogue [11C]hydroxyephedrine
([11C]HED) (14) and the beta-antagonist [11C]CGP 12177 (15)
(Fig. 1).
Methods
Subjects. Study patients. Eight patients (six women, two
men; mean 6 SD age 44 6 11 years, range 26 to 55, median 49)
with documented recurrent RVO-VT were investigated.
Patient characterization. RVO-VT was diagnosed on the
basis of documented sustained or nonsustained ventricular
tachycardia of left bundle branch block configuration and
inferior QRS axis originating in the right ventricular outflow
tract as determined by the configuration of ventricular tachy-
cardia and by endocardial mapping during an electrophysi-
ologic study. Two-dimensional echocardiography, left and
right ventricular angiography, coronary angiography and en-
domyocardial biopsy were performed to exclude morphologic,
functional and structural heart disease, including coronary
artery disease, hypertrophic or dilated cardiomyopathy; and
congenital, valvular and inflammatory heart disease (3,5). All
patients were in sinus rhythm with normal 12-lead electrocar-
diograms at rest. In particular, no patient had bundle branch
block, left ventricular hypertrophy or a prolongation of the QT
interval. Signal-averaged electrocardiograms were normal in
all patients (16). All patients underwent an invasive electro-
physiologic study, including programmed ventricular stimula-
tion with up to three extrastimuli and additional isoproterenol
infusion (12,17). Ventricular tachycardia was sustained in two
patients (25%). Monomorphic ventricular tachycardia was
provocable by physical exercise in six patients and by intrave-
nous isoproterenol infusion in four (Table 1).
Control groups. Two groups of age-matched control sub-
jects were studied. For the studies with [11C]HED and oxygen-
15–labeled water (H2[
15O]), the control group included 10
subjects (mean age 35 6 7 years, range 23 to 46, median 33,
p 5 NS vs. patients). For the [11C]CGP 12177 scans, a control
group of 19 volunteers (mean age 44 6 16 years, range 21 to
65, median 45, p 5 NS vs. patients) was investigated. All
control subjects had no history of cardiac disease, a low risk
profile and normal examination results. All had normal rest
ECGs and negative exercise tests in response to a high
workload.
Informed consent. All study patients and control subjects
gave written informed consent to the study protocol, which was
approved by the Hammersmith Hospital Research Ethics
Committee and the United Kingdom Administration of Ra-
dioactive Substances Advisory Committee (ARSAC).
Study protocol. Subject preparation. Measurement of car-
diac presynaptic and postsynaptic sympathetic function was
performed in the same subject on 2 consecutive days. The
patients took no medication for at least 24 h. No patient had
previously received beta-adrenergic blocking agents.
Data acquisition. Cardiac presynaptic norepinephrine re-
uptake and postsynaptic beta-adrenoceptor density were as-
sessed by dynamic positron emission tomography (PET)
(ECAT 931-08/12, Siemens/CTI) using the norepinephrine
analogue [11C]HED and the nonselective (;80% beta1) hy-
drophilic beta-adrenoceptor antagonist [11C]CGP 12177 (4-(3-
t-butylamino-2-hydroxypropoxy)-benzimidazol-2-1) (15). In
addition, rest myocardial blood flow (MBF) was assessed using
H2[
15O] (18).
The left ventricle was centered in the field of view by means
of a rectilinear scan recorded during the exposure of external
germanium-68 ring sources. This was followed by a transmis-
sion scan of 20 min in duration for attenuation correction. A
blood volume scan (ml blood/ml region of interest) was then
performed using inhalation of oxygen-15–labeled carbon mon-
oxide (C[15O]) delivered through a face mask at a constant rate
of 500 ml/min and a radioactive concentration of 3 MBq/ml
over 4 min. After 1 min, to allow for tracer equilibration, a
6-min emission scan was initiated, during which four venous
blood samples were taken to measure blood radioactivity.
Day 1. Presynaptic norepinephrine reuptake was measured
by intravenous administration of [11C]HED prepared by direct
Figure 1. Scheme of presynaptic and postsynaptic sympathetic inner-
vation. The norepinephrine (NE) analogue [11C]HED was used for
measuring presynaptic reuptake of norepinephrine (UP), and the
nonselective beta-blocker [11C]CGP 12177 was used for measuring
postsynaptic beta-adrenoceptor (b-AR) density.
Abbreviations and Acronyms
Bmax 5 maximal binding capacity
BGO 5 bismuth germanate
[11C]HED 5 [11C]hydroxyephedrine
MBF 5 myocardial blood flow
[123I]MIBG 5 [123I]meta-iodo-benzylguanidine
PET 5 positron emission tomography (tomographic)
ROI 5 region of interest
RVO-VT 5 right ventricular outflow tract tachycardia
Vd 5 volume of distribution
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N-methylation of metaraminol with [11C]methyliodide in sul-
foxide (14). The compound was purified using high perfor-
mance liquid chromatography to provide an isotonic buffered
aqueous solution for injection with high specific activity, re-
sulting in low injectate levels of HED and precursor (3.2 6 1.7
and 0.5 6 0.3 mg, respectively) and a radiochemical purity
.99.5%. [11C]HED (352 6 36 MBq) was infused intravenously
over a period of 1 min. The amount of injected (radioactive
and molar) HED was not different between patients and
control subjects. During the dynamic scan of 65 min (frames:
1 3 30 [background], 6 3 5, 6 3 10, 3 3 20, 4 3 30, 5 3 60,
4 3 150 and 9 3 300 s), arterialized venous blood was sampled
at a rate of 2.5 ml/min from the vein of a heated hand by means
of a peristaltic withdrawal pump and a bismuth germanate
(BGO) detection system for monitoring the arterial input
function (19). Additional samples of arterialized blood were
taken to calibrate the BGO detection system, measure whole
blood/plasma ratios and assay HED metabolites in plasma.
MBF was measured by an intravenous bolus of 555 MBq
H2[
15O] (frames: 1 3 30, 1 3 20, 14 3 5, 3 3 10, 3 3 20, and
4 3 30 s) (18).
Day 2. Postsynaptic beta-adrenoceptor density was as-
sessed using [11C]CGP 12177, as previously described (20–22).
Briefly, a first dose of [11C]CGP 12177 with high specific
activity (161.8 6 26.4 MBq, 5.4 6 1.9 mg of cold CGP 12177)
was infused intravenously over 2 min (frames: 1 3 30 [back-
ground], 8 3 15, 4 3 30, 2 3 60, 2 3 120 and 8 3 150s). Thirty
minutes later, a second dose with low specific activity (311.7 6
63.5 MBq, 27.7 6 6.7 mg of cold CGP 12177) was infused
intravenously over 2 min (frames: 8 3 15, 4 3 30, 2 3 60, 2 3
120 and 14 3 150 s). The amount of CGP 12177 injected
(radioactive and molar) was not different between patients and
control subjects. Venous blood was sampled from the antecu-
bital vein using the BGO detection system, as described earlier.
Additional blood samples were taken to calibrate the BGO
detection system and to measure whole blood/plasma ratios at
10, 25, 45, 60 and 75 min after injection.
Data analysis. Raw scan data were stored on a MicroVax II
computer (Digital Equipment Corporation), then transferred
to a SUN workstation for normalization, attenuation correc-
tion and reconstruction. The resulting images were further
analyzed using software developed under the MatLab mathe-
matical software package (The MathWorks Inc.). Images were
resliced by defining the heart axis in the vertical and horizontal
long-axes views. Twelve slices were defined between the visu-
ally defined base and apex of the heart to obtain anatomically
standardized regions. On the short-axis slices, inner and outer
myocardial borders were traced manually. Sixteen ROIs were
automatically defined for regional analysis. For the analysis of
the whole left ventricle, all regions were grouped together. In
addition, regions were drawn within the left atrium on at least
three consecutive planes for arterial input data. All ROIs were
then applied to all dynamic emission images to generate
time–activity curves.
Myocardial blood volume. Myocardial blood volume (ml/ml
ROI) was determined by relating the regional concentration of
radioactivity in the C[15O] scan to the mean concentration of
radioactivity in the blood samples (a value of 1.06 g/ml was
assumed for the density of blood). Extravascular tissue volume
(ml tissue/ml ROI) was calculated by subtracting the vascular
density image from the normalized transmission scan (18).
MBF. MBF was calculated using a single-compartment
model (18). From the H2[
15O] scan data, the perfused tissue
fraction (ml exchangable tissue/ml ROI) was calculated to
correct the [11C]HED scan for partial volume effects.
Presynaptic neuronal norepinephrine reuptake. Uptake-1 was
assessed by the volume of distribution (Vd) of [
11C]HED using
a single-tissue compartment model and least-square nonlinear
regression to provide influx and efflux rate constants K1 and k2,
where Vd 5 K1/k2. The arterial input function was obtained
from the left atrium for the first 15 min after the start of
injection and from the BGO counting system afterward. This
was necessary because of the net extraction of tracer from
blood in the heated hand in the first phase and the low blood
count rate and increasing myocardial spillover into the left
atrial ROI at later times. The later part of the BGO curve was
used to correct for the spillover of radioactivity into the left
atrium. Plasma metabolite concentrations were determined by
high performance liquid chromatography and used to correct
the plasma [11C]HED input curves. The resulting values of Vd
(ml/ml ROI) were regionally corrected for partial volume and
heart motion effects using the measured values of tissue
Table 1. Patient Characteristics
Pt No./
Gender
Age
(yr) VT
CL
(ms)
Hx of
VT (mo) Sync VT on Ex VT on Iso VT on EPS
1/F 33 nsVT 220 82 2 1 1 2
2/F 53 sVT 300 48 (1) 2 2 2
3/F 55 nsVT 370 103 2 2 2 nsVT
4/M 53 nsVT 300 78 2 1 1 nsVT
5/F 45 sVT 400 12 (1) 2 2 nsVT
6/F 26 nsVT 330 22 1 1 2 2
7/M 36 nsVT 330 54 2 2 1 2
8/F 54 nsVT 310 36 2 1 2 2
CL 5 cycle length; EPS 5 electrophysiologic study; Ex 5 exercise; Hx 5 history; Iso 5 isoproterenol infusion; Pt 5
patient; Sync 5 syncope (2 5 no, 1 5 yes); VT 5 ventricular tachycardia (s 5 sustained; ns 5 nonsustained); (1) 5
pre syncope.
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fraction obtained from the MBF scan. These values were then
converted from units of ml/ml to units of ml/g by dividing by
the myocardial tissue density (1.04 g/ml tissue).
Postsynaptic beta-adrenoceptor density. Adrenoceptor den-
sity was estimated by measurement of the maximal binding
capacity (Bmax) (pmol/g) of the beta-adrenoceptor antagonist
[11C]CGP 12177. The two sections of the curve corresponding
to the slow clearance of tracer from tissue, which repre-
sent the dissociation of [11C]CGP 12177 bound to beta-
adrenoreceptors after each injection, were exponentially ex-
trapolated on the y-axis back to the start of each infusion. Bmax
was calculated using a modification of the equation described
by Delforge et al. (20) to take account of the molar content of
[11C]CGP 12177 in both injections (21,22). Time–activity
curves were corrected for decay and spillover of radioactivity
from blood to the myocardium using the blood volume image
and the blood time–activity curves. Bmax was corrected for the
partial volume effect by normalizing it to the regional values of
extravascular tissue volume (ml tissue/ml ROI) obtained from
the blood volume and transmission scans. The myocardial
beta-adrenoceptor density values were then converted from
units of pmol/ml tissue to pmol/g tissue by dividing it by the
density of myocardial tissue (1.04 g/ml tissue).
Hemodynamic variables and plasma norepinephrine. During
the scans, heart rate, heart rhythm (12-lead ECG) and blood
pressure were monitored at 15-min intervals. Plasma norepi-
nephrine was measured at the beginning and end of each
scanning procedure.
Statistical analysis. Results are expressed as mean value 6
standard deviation. After testing for the equality of variances
(Levene test, SPSS), the Student t test was used for the
comparison between groups for the values of Vd of [
11C]HED,
Bmax of [
11C]CGP 12177, MBF and hemodynamic and serum
variables. The coefficient of variation was used to test for
regional differences of left ventricular distribution of
[11C]HED and [11C]CGP 12177. A p value of 0.05 was
considered significant.
Results
Hemodynamic variables and plasma norepinephrine.
There were no differences between patients and control sub-
jects concerning heart rate and systolic and diastolic blood
pressure at baseline and during the scans. A 12-lead ECG
recording confirmed the absence of ventricular tachycardia
during scanning in all patients. Plasma norepinephrine levels
were constant during the scans and were not different from
those in the control group (1.20 6 0.61 vs. 1.41 6 0.68
nmol/liter, p 5 NS).
MBF. Whole-heart MBF was similar in patients and con-
trol subjects (0.98 6 0.14 vs. 0.97 6 0.24 ml/min per g, p 5 NS),
and no regional differences were observed in either group.
Myocardial sympathetic function. Global Vd of HED and
Bmax of CGP 12177 were significantly reduced in patients with
RVO-VT compared with that in control subjects (Vd of HED
41.0 6 13.5 vs. 71.0 6 18.8 ml/g, p , 0.002; Bmax of CGP 12177
6.8 6 1.2 vs. 10.1 6 2.9 pmol/g, respectively, p , 0.004) (Fig.
2 and 3). There was no significant correlation between presyn-
aptic and postsynaptic function in each patient (r 5 0.38, p 5
NS). No regional differences in the Vd of HED and Bmax of
CGP 12177 were observed in either group.
Discussion
The most likely pathophysiologic mechanism of ventricular
tachycardia in patients with idiopathic RVO-VT is a cyclic
adenosine monophosphate–dependent increase in intracellu-
lar Ca ions, with subsequent delayed afterdepolarization
(23,24). This is supported indirectly by the proarrhythmic effect
of beta-adrenergic agonists (e.g., isoproterenol), which stimu-
late adenylyl cyclase activity, as well as by the finding that
tachycardia can be terminated by substances such as adeno-
sine, which inhibit adenylyl cyclase. In the present study, we
showed that presynaptic reuptake of norepinephrine and
postsynaptic beta-adrenoceptor density are globally reduced
in the left ventricular myocardium of patients with RVO-VT
and that, in the same subjects, myocardial perfusion at rest
was normal. Reduced catecholamine reuptake and beta-
adrenoreceptor density have also been described in different
forms of cardiomyopathies and postischemic heart failure as
well as in dysautonomias (25–31). In these diseases, the
changes in presynaptic and postsynaptic sympathetic innerva-
tion are probably consequent to the functional and structural
abnormalities of the heart. In contrast, in patients with idio-
Figure 2. Norepinephrine reuptake measured by Vd of [
11C]HED in
patients with RVO-VT and control subjects (mean value is indicated
by horizontal lines).
Figure 3. Bmax for beta-adrenoceptors measured using [
11C]CGP
12177 in patients with RVO-VT and control subjects (mean value is
indicated by horizontal lines).
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pathic RVO-VT, no functional or structural abnormality is
detectable: patients with RVO-VT typically show no sign of
heart failure and exhibit normal plasma norepinephrine levels
(23). The same investigators found an increased sympathetic
activity before the onset of arrhythmias in patients with
RVO-VT, by analysis of heart rate variability without changes
in parasympathetic activity. A local increase in norepinephrine
in the synaptic cleft can in theory be explained by two
mechanisms: 1) an increase in presynaptic release, and 2) a
reduced presynaptic reuptake (uptake-1) (32). The finding of
the present study, that the Vd of [
11C]HED is significantly
reduced does not allow discrimination between increased
neuronal release and reduced reuptake. In fact, the Vd of
[11C]HED, which is defined as the ratio of neuronal influx and
efflux, can be reduced because of decreased influx (uptake-1)
or increased efflux (neuronal release) (32).
The reduced density of myocardial beta-adrenoceptors
demonstrated by PET in the present study is consistent with an
increased concentration of norepinephrine in the synaptic
cleft. Ventricular tachycardia in patients with RVO-VT can be
triggered by exercise, which is accompanied by increased
sympathetic activity, or by direct catecholamine administration
(7). This finding suggests that despite beta-adrenoceptor
downregulation, norepinephrine is still capable of increasing
significantly the intracellular cyclic adenosine monophosphate
concentration, probably due to changes in the beta-
adrenoceptor–G-protein–adenylyl cyclase pathway (Fig. 4)
(33).
Study limitations. The important link between presynaptic
and postsynaptic adrenergic function, namely, the norepineph-
rine concentration in the synaptic cleft, cannot be measured
noninvasively in vivo. Because neither norepinephrine spill-
over nor efferent sympathetic activity, (e.g., by means of
microneurography) was measured in the present study, the
existence of locally high catecholamine concentrations in the
synaptic cleft as the primary cause of beta-adrenoceptor down-
regulation in our patients with RVO-VT cannot be proved.
Because of the limited spatial resolution of the PET
scanner, it was not possible to perform accurate measurements
in the thin right ventricular wall. Therefore, we could not
ascertain whether presynaptic and postsynaptic sympathetic
nerve function were abnormal in the right ventricle, which is
known to be the origin of the arrhythmia in these patients (3).
Preliminary studies in conscious dogs (34) submitted to rapid
right ventricular pacing for 1 day demonstrated a significant
increase in efferent sympathetic activity directed to the heart
that was abolished by selective left ventricular denervation.
This finding suggests that a stimulus originating from the right
ventricle can be associated with an increased efferent activity to
the whole heart and is in line with the findings of the present
study.
Regional sympathetic denervation, previously shown by
[123I]MIBG in ;70% of patients (11), was not confirmed in the
present investigation. However, no patient in the present study
was previously investigated with [123I]MIBG, and therefore a
direct comparison is not possible.
Although the number of patients studied is small, they
represent a carefully selected cohort because patients with
previous treatment with beta-blockers or undergoing catheter
ablation were excluded.
Conclusions. The results of the present study show that in
patients with idiopathic RVO-VT, both presynaptic catechol-
amine reuptake and postsynaptic beta-adrenoceptor density
are reduced. These findings support previous results of locally
increased sympathetic activity, most likely due to increased
local catecholamine levels in the synaptic cleft, and may play a
role in the pathophysiology of the tachycardia.
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